The panobinostat expansion (PANEX) treatment protocol (n [ 39) provided access to panobinostat and gathered additional efficacy and safety data on the panobinostat, bortezomib, dexamethasone regimen before commercial availability. The findings from the study supported those that led to regulatory approval of the regimen. Additionally, the use of subcutaneous bortezomib in the PANEX trial resulted in potential tolerability benefits, including a relatively low rate of peripheral neuropathy. Background: Panobinostat was recently approved by the US Food and Drug Administration and European Commission in combination with bortezomib and dexamethasone for patients with multiple myeloma who have received ! 2 regimens, including bortezomib and an immunomodulatory drug. The PANEX (panobinostat expansion) treatment protocol provided access to panobinostat and gathered additional safety data before commercial availability. Patients and Methods: In treatment phase 1, patients received panobinostat 20 mg 3 times per week plus bortezomib 1.3 mg/m 2 twice weekly with dexamethasone 20 mg on the days of and after bortezomib treatment.
Introduction
Significant improvements have been made during the past decade in the treatment of multiple myeloma (MM), leading to improved patient outcomes and a wealth of new therapeutic options. 1, 2 However, owing to the multiclonal nature of the disease, most patients will eventually develop relapse or refractory disease to ! 1 therapeutic regimens, leading to a poorer prognosis and diminishing treatment options. 3, 4 Thus, a substantial unmet need remains for agents with novel mechanisms of action to overcome disease resistance. Panobinostat (PAN), a potent pan-deacetylase inhibitor, targets aberrations in MM cells through modulation of dysregulated gene expression (eg, tumor suppressor genes) and the inhibition of protein metabolism through the aggresome pathway. [5] [6] [7] Furthermore, evidence has suggested that the marked synergy observed between PAN and the proteasome inhibitor bortezomib (BTZ) is mediated not only through dual inhibition of protein metabolism but also through epigenetic methods. [7] [8] [9] [10] [11] [12] In the pivotal phase III PANORAMA-1 (panobinostat or placebo with bortezomib and dexamethasone in patients with relapsed multiple myeloma) trial, the addition of PAN to BTZ and dexamethasone (PAN-BTZ-Dex) led to a statistically significant and clinically meaningful progression-free survival benefit of z 4 months compared with placebo plus BTZ and Dex. 13 Patients with BTZ-refractory disease were excluded from that study. The most substantial benefit was observed in a subpopulation of patients who had received ! 2 previous therapeutic regimens, including BTZ and an immunomodulatory drug, in which a progression-free survival benefit of 7.8 months with PAN-BTZ-Dex compared with placebo-BTZ-Dex was observed. 14 These results led to the recent US Food and Drug Administration and European Commission approvals of PAN in combination with BTZ and Dex for the treatment of patients with relapsed or relapsed and refractory MM who have received ! 2 previous regimens, including BTZ and an immunomodulatory drug. The PANEX (panobinostat expansion) treatment protocol was designed to provide access to PAN and to gather additional safety and efficacy data on the PAN-BTZ-Dex regimen before commercial availability in the United States. Unlike PANORAMA-1, in which BTZ administration was exclusively intravenous, PANEX was designed to allow investigators to choose the route of BTZ administration and represents the first experience with PAN combined with subcutaneous BTZ. The use of subcutaneous BTZ has been associated with an improved safety profile compared with intravenous administration, including a significant reduction in peripheral neuropathy frequency and a reduction in the number of gastrointestinal adverse events (AEs). 15 
Patients and Methods
The present multicenter, open-label, expanded-treatment protocol of PAN-BTZ-Dex enrolled adult patients (aged ! 18 years) with MM that had relapsed and/or was refractory to ! 1 previous therapy regimens. The key inclusion criteria included an Eastern Cooperative Oncology Group (ECOG) performance status of 2, adequate hepatic function, and no worse than moderate renal impairment (creatinine clearance [CrCl] , ! 40 mL/min). Patients with primary refractory disease or disease refractory to previous BTZ were allowed. Patients were ineligible if they were intolerant of any of the study medications, had known contraindications, presented with grade ! 2 peripheral neuropathy or diarrhea, or had impaired cardiac function. Patients receiving concomitant anticancer therapy, drugs known to prolong the QT interval that could not be discontinued, anticoagulants (thrombin inhibitors and factor Xa inhibitors), or antimyeloma therapy, including immunomodulatory drug or Dex within 3 weeks of randomization, were excluded.
Treatment was divided into 2 treatment phases (TPs; Figure 1 ). TP1 consisted of eight 21-day cycles, during which oral PAN 20 mg was administered once daily on days 1, 3, 5, 8, 10, and 12. Dose adjustments for PAN (in 5-mg decrements to a minimum dose of 10 mg) were permitted for observed toxicity. Patients who could not tolerate 10 mg were required to discontinue treatment. BTZ (1.3 mg/m 2 ) was administered either intravenously or subcutaneously at the discretion of the investigator twice weekly on days 1, 4, 8, and 11, with oral Dex (20 mg) given on the day of and the day after BTZ administration. Patients completing all 8 cycles of TP1 and achieving at least no change (NC) continued to TP2. During TP2, dosing and administration of PAN remained constant, and BTZ administration was reduced to once weekly on days 1 and 8, with Dex given on the day of and the day after BTZ. Patients achieving at least NC during TP1 were permitted to switch to once-weekly BTZ before cycle 8 at the discretion of the treating investigator. Patients completing all eight 21-day cycles of TP2 and achieving at least NC were permitted to continue with the study medication until September 2015 or until PAN became commercially available, whichever occurred first. Patients continued in the study until the occurrence of unacceptable toxicity or disease progression or the end of the study. A comprehensive diarrhea management protocol was used to mitigate treatment-related symptoms (Figure 2) .
The primary objective was to assess safety through monitoring of hematology parameters, vital signs, physical condition, body weight, ECOG performance status, and cardiac assessment. Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4. The secondary objective was to assess the clinical efficacy through the investigator-assessed overall response rate (ORR), defined as at least a partial response (PR) using the modified European Blood and Marrow Transplantation criteria, 16 and clinical benefit rate. The response during therapy was assessed by monitoring of serum and urine M protein, bone marrow aspirate plasma cell count, serum and urine immunofixation, free light-chain analysis, bone radiography, evaluation of soft tissue plasmacytomas, and serum calcium measurement. The final analysis was performed after all patients had been followed up for an additional 28 days after either prematurely discontinuing therapy or completing treatment according to the protocol. 
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Results
Baseline Demographic Data and Disease History
A total of 39 patients with a median age of 70 years (range, 44-88 years) were enrolled in the PANEX study (Table 1) . Most patients were men (23 of 39 [59%]) and had an ECOG performance status of ! 1 (28 of 39 [72%]). Of the 39 patients, 10 (26%) had a baseline CrCl of 40 to 59 mL/min. The patients had been heavily pretreated, with a median of 4 (range, 1-12) previous treatment regimens; 15 of 39 patients (38%) had received ! 5 previous therapies.
Administration and Exposure to Study Medication
Most patients (34 of 39 [87%]) received subcutaneous BTZ instead of intravenous administration (13%; Table 2 ). Dose adjustment for AEs was required for most patients, with dose changes in PAN, BTZ, and Dex in 23 (59%), 23 (59%), and 18 (46%) of the 39 patients, respectively. Although most patients required some alteration of dosing, overall, the patients received close to the planned dose amount for each drug, with a relative dose intensity of 86% (range, 33%-117%) for PAN, 87% (range, 29%-132%) for BTZ, and 91% (range, 36%-113%) for Dex. The median treatment duration was 8.1 weeks (range, 1-33 weeks). Of the 39 patients, 11 (28%) discontinued therapy because of AEs. Other reasons for discontinuation included disease progression (26%), transition to commercial supply (23%), withdrawal of consent (13%), abnormal laboratory value (3%), and death (3%).
Safety
Nearly all patients (94.9%; 95% confidence interval [CI], 88.0%-100%) experienced ! 1 grade 3/4 treatment-emergent AE during the study (Table 3) . The most common grade 3/4 hematologic laboratory-defined AEs in the overall population were thrombocytopenia (54%), neutropenia (15%), and anemia (15%). For the 34 patients receiving subcutaneous BTZ, the most common grade 3/4 hematologic AEs were thrombocytopenia (47%), neutropenia (18%), and anemia (15%). The most common grade 3/4 nonhematologic AEs in the overall population included fatigue (31%), dehydration (26%), diarrhea (18%), pneumonia (13%), and syncope (13%). Among the 34 patients receiving subcutaneous BTZ, the most common grade 3/4 nonhematologic AEs were fatigue (29%), dehydration (21%), pneumonia (15%), syncope (15%), diarrhea (12%), and nausea (12%). The dehydration observed in the present trial was almost exclusively associated with diarrhea, nausea, and/or vomiting. The key PAN-BTZDexeassociated all-grade AEs in patients receiving subcutaneous BTZ included asthenia (21%), pneumonia (21%), vomiting (18%), and peripheral neuropathy (15%; Table 4 ).
In an analysis of the 10 patients with moderate renal impairment (CrCl, 40-59 mL/min), no obvious increase in toxicity was observed compared with the 29 patients with a CrCl of ! 60 mL/min Table 1 ; available in the online version). The common AEs were similar in the patients with a CrCl of 40 to 59 mL/min versus ! 60 mL/min, including fatigue (40% vs. 28%), diarrhea (0% vs. 24%), dehydration (40% vs. 21%), syncope (0% vs. 17%), and pneumonia (10% vs. 14%). However, because the patient numbers are limited, these data should be interpreted with caution.
The most common AEs leading to dose adjustment or interruption in the overall population were diarrhea (31%), thrombocytopenia (26%), fatigue (26%), anemia (18%), and dehydration (15%). Diarrhea (2 of 39 [5.1%]) was the most common AE leading to study drug discontinuation. No other AE led to discontinuation in > 1 patient. One patient died during the study of respiratory arrest that was determined by the investigator to be unrelated to the study drug.
An analysis of platelet kinetics stratified by the route of BTZ administration demonstrated a rebound in platelet values after the treatment-free week of each cycle, regardless of the route of BTZ administration (Figure 3 ). This platelet rebound is characteristic of PAN-BTZ-Dex therapy. No cumulative effect of the regimen on platelet counts was observed during the course of the study.
Efficacy
In the overall population, 22 of 39 patients achieved a PR, for an ORR of 56% (95% CI, 41%-72%; Table 5 ). A total of 7 additional patients (18%) had a best response of minimal response 
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(MR) and 9 patients (23%) had a best response of NC (NC or better, 97.4%; 95% CI, 92.5%-100%). The response was unknown for 1 patient who had died of pneumonia/respiratory arrest before the assessment could be completed. All the patients included in the trial achieved a best response of stable disease or better. Among the 34 patients receiving subcutaneous BTZ, 21 had a best response of a PR, for an ORR of 62% (95% CI, 45%-78%; Table 5 ). Nearly all of the 34 patients receiving subcutaneous BTZ had a best response of NC or better (97.1%; 95% CI, 91.4%-100%), with 5 (15%) achieving a best response of MR and 7 (21%) achieving a best response of NC. One patient had an unknown response. Of the 10 patients with moderate renal impairment (CrCl, 40-59 mL/min), 4 achieved a PR, for an ORR of 40% (95% CI, 10%-70%) versus 62% (95% CI, 44%-80%; 18 of 29 patients with a PR) in patients with a CrCl of ! 60 mL/min (Supplemental Table 2 ; available in the online version). Among the patients with a CrCl of 40 to 59 mL/min, an additional 2 patients (20%) achieved a best response of MR and 4 patients (40%) had a prolonged NC (NC or better, 100%; 95% CI, 100%-100%). Although these results suggest clinical benefit for patients with moderate renal impairment treated with PAN-BTZ-Dex, the results should be interpreted with caution because the patient numbers in this exploratory cohort were small. However, these results could warrant further confirmation in a larger cohort.
Discussion
The regimen of PAN-BTZ-Dex has demonstrated clear efficacy benefit in patients with heavily pretreated MM. However, concerns were raised during the regulatory approval process regarding the tolerability of the regimen. The present study has provided the first evidence of the safety and efficacy of PAN-BTZ-Dex outside of a randomized clinical trial setting and represents the first report of the use of this regimen with subcutaneous BTZ.
The overall safety profile of the regimen in the PANEX trial was predictable, manageable, and consistent with the safety results observed in previous trials. The most common grade 3/4 AEs included thrombocytopenia (54%), fatigue (31%), dehydration (26%), and diarrhea (18%). Thrombocytopenia was manageable and reversible, with a characteristic platelet count rebound during the off-treatment week of each cycle, regardless of the route of BTZ administration. Dehydration was observed with moderate frequency and was almost exclusively associated with gastrointestinal AEs, including diarrhea, nausea, and vomiting. Subcutaneous administration of BTZ in a cohort of 34 patients was associated with favorable rates of some key AEs, including grade 3/4 thrombocytopenia (47%) and diarrhea (12%). Although the favorable rates of grade 3/4 diarrhea observed in the present study could potentially have resulted from the route of BTZ administration, the aggressive diarrhea management protocol could also have contributed to reducing the grade 3/4 rates and could be a model for diarrhea management in the community setting. The overall short duration of therapy despite achieving a high relative dose intensity was because most discontinuations resulted from progressive disease, as would be expected in this highly refractory patient population. Nevertheless, the overall low rates of discontinuations due to AEs (n ¼ 11), when considered in conjunction with the high relative dose intensity, further support the tolerability of this regimen. In a heavily pretreated population (median number of previous regimens, 4; range, 1-12), PAN-BTZ-Dex demonstrated marked clinical benefit, with an ORR of 56% and 97% with NC or better in the overall population. This benefit was consistent, regardless of the route of BTZ administration, with an ORR of 62% and NC or better rate of 97% in patients receiving subcutaneous BTZ. Furthermore, the present study has demonstrated the preliminary efficacy and feasibility of PAN-BTZ-Dex in the treatment of patients with moderate renal impairment, with no obvious increases in toxicity and with all patients achieving a best response of NC or better in this subset of patients. Previously, BTZ had been demonstrated to potentially alleviate some MM-related renal impairment and to overcome the poor prognosis in patients with moderate to severe renal impairment. [17] [18] [19] Therefore, further investigation of the regimen in patients with renal impairment could be warranted. Some key differences were observed between the patient population in the present study and that in PANORAMA-1. Overall, the patients in the expanded-treatment protocol had worse prognostic features at baseline and had been more heavily pretreated than had the patients in the PAN arm of the PANORAMA-1 trial. 13 The patients in the present trial were older (median age, 70 and 63 years in PANEX and PANORAMA-1, respectively), had a higher ECOG performance status at baseline (! 1, 72% for PANEX and 54% for PANORAMA-1), and were more heavily pretreated (median number of previous regimens, 4 in PANEX and 1 in PANORAMA-1). The disease history of the patients in the PANEX trial aligned more closely with that of patients in the earlier phase II PANORAMA-2 trial of PAN-BTZ-Dex in a similar setting, including treatment history (median previous regimens, 4 for PANORAMA-2) and the inclusion of patients with disease refractory to BTZ, who were not permitted in the PANORAMA-1 trial. 20 Although the patient numbers in the present trial were limited, it is intriguing that despite the poorer baseline prognostic features, the overall clinical response and safety were similar to those observed in the PAN arm of PANORAMA-1. The ORR observed in the overall population in the present trial appeared similar to that in PANORAMA-1 (56% and 61%, respectively). 13 Additionally, the rates of key AEs, including grade 3/4 thrombocytopenia (54% in PANEX and 67% in PANORAMA-1) and diarrhea (18% in PANEX and 25% in PANORAMA-1), were similar to, or improved compared with, the rates observed in PANORAMA-1. The safety results in the present trial were also similar to those observed in the PANORAMA-2 trial, including grade 3/4 thrombocytopenia (64%) and diarrhea (20%). Also, the clinical response favored the present trial (ORR, 56% for PANEX; 35% for PANORAMA-2), although the patients in the present trial did not exclusively have disease refractory to BTZ. 20 Subcutaneous BTZ had been previously reported to demonstrate noninferior efficacy and a reduction in the frequency of some AEs compared directly with intravenous BTZ. 15 In the present trial, the response rate observed in the subgroup of patients receiving subcutaneous BTZ (ORR, 62%; 95% CI, 45%-78%) was similar to that in patients receiving intravenous BTZ in PANORAMA-1 (ORR, 62% and 61% in PANEX and PANORAMA-1, respectively). 13, 20 The rates of some key grade 3/4 AEs appeared to be reduced with subcutaneous BTZ in the present trial compared with intravenous BTZ administration in PANORAMA-1 and PANORAMA-2, including thrombocytopenia (47%, PANEX; 67%, PANORAMA-1; 64%, PANORAMA-2) and diarrhea (12%, PANEX; 25%, PANORAMA-1; 20%, PANORAMA-2). Furthermore, the rate of peripheral neuropathy in patients receiving PAN plus subcutaneous BTZ in the expanded-treatment protocol (15%) compared favorably with the rate observed in patients receiving subcutaneous BTZ alone (35%). 15 Taken together, these results suggest that the incorporation of subcutaneous BTZ in the PAN-BTZ-Dex regimen could provide an equivalent response and spare patients some notable toxicity, although further evaluation in a larger cohort is warranted.
Conclusion
Overall, the data from the present study support those generated from PANORAMA-1. Further clinical experience with subcutaneous BTZ in this combination should help inform the effect of the route of BTZ administration on the efficacy and tolerability of this regimen.
Clinical Practice Points
PAN was recently approved by the US Food and Drug Administration and European Commission in combination with BTZ and Dex for patients with MM who have received ! 2 previous regimens, including BTZ and an immunomodulatory drug. The PANEX treatment protocol provides the first evidence of the safety and efficacy of PAN-BTZ-Dex outside of a randomized clinical trial setting and represents the first report of the use of this regimen with subcutaneous BTZ. The overall safety profile of the regimen in the PANEX trial was predictable, manageable, and consistent with the safety results observed in previous trials. Most patients (87%) received subcutaneous BTZ, which was associated with favorable rates of key AEs. PAN-BTZ-Dex in PANEX demonstrated marked clinical benefit in a heavily pretreated patient population, consistent with the efficacy results from previous trials.
Data from PANEX support regulatory approval of PAN plus BTZ and Dex and suggest potential tolerability benefits with subcutaneous BTZ in this regimen.
